SAN DIEGO, Dec. 13, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that two studies conducted by outside investigators that involved the Company's antibody drug candidates were presented at the 53rd Annual Meeting of the American Society of Hematology.
